Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1988-08-24
1990-04-03
Schwartz, Richard A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
548309, 548311, A61K 31415, C07D23380
Patent
active
049140990
ABSTRACT:
The present invention relates to novel hydantoin derivatives, processes for producing said hydantoin derivatives, pharmaceutical compositions containing at least one of said hydantoin derivatives as aldose reductase inhibitors and novel intermediate compounds in the synthesis of said hydantoin derivatives.
The present invention is based on the selection of a hydantoin which is bonded by a sulfonyl group to various substituents at the 1-position of the hydantoin skeleton.
REFERENCES:
patent: 3384643 (1968-05-01), Sayigh et al.
patent: 3534022 (1970-10-01), Umemoto et al.
patent: 4743611 (1988-05-01), Malamas et al.
Chemical Abstracts, vol. 95, No. 15, Oct. 12, 1981, Abstract No. 132725m.
Chemical Abstracts, vol. 97, No. 1, Jul. 5, 1982, Abstract No. 6774e.
Chemical Abstracts, vol. 99, 1983, Abstract No. 116079f.
Chemical Abstracts, vol. 107, 1987, Abstract No. 59037y.
Chemical Abstracts, vol. 109, 1988, Abstract No. 129004c.
Kato Katsuaki
Kato Kazuo
Miwa Ichitomo
Mochida Ei
Okuda Jun
Mochida Pharmaceutical Co. Ltd.
Schwartz Richard A.
LandOfFree
Hydantoin derivatives as aldose reductase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydantoin derivatives as aldose reductase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydantoin derivatives as aldose reductase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1357749